Previous close | 20.45 |
Open | N/A |
Bid | 8.20 |
Ask | 16.00 |
Strike | 160.00 |
Expiry date | 2025-07-18 |
Day's range | 20.45 - 20.45 |
Contract range | N/A |
Volume | |
Open interest | N/A |
ACTON, Mass., June 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin del
ACTON, Mass., June 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as
On June 14, 2024, Mark Field, Senior Vice President & Chief Technology Officer of Insulet Corp (NASDAQ:PODD), executed a sale of 1,500 shares of the company.